Similarly, ivosidenib, an oral mutant IDH1 inhibitor, has shown durable remissions and favorable tolerability in relapsed or refractory IDH1-mutated AML (NCT02074839) [64]. This evidence concerns the gene IDH1 and acute myeloid leukemia.